Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTPOWER: Inetetamab in HER2+ Breast Cancer
NCT06578299Phase 4Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of inetetamab in breast cancer, sponsored by Fudan University. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06578299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578299.